Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05408091 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
A Phase 1 study, sponsored by Trellis Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05408091: Completed Phase 1 study, sponsored by Trellis Bioscience.
NCT05408091 is a Phase 1 study that has completed, run by Trellis Bioscience. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05408091, a Phase 1 study, has completed, sponsored by Trellis Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data, and provide serum samples for ex vivo studies of concentration-dependent antiviral activity to support the dose selection for as well as design and conduct of a clinical study in transplant patients.
Primary Outcome
Clinically-significant abnormal physical exam findings will be reviewed
Interventions
- DRUG TRL345, a human monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 1 |
What the finished NCT05408091 record still lists
NCT05408091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which TRL345, a human monoclonal antibody is the first listed.
NCT05408091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05408091 about?
NCT05408091 is a clinical study titled "Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers". This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data, and provide serum samples for ex vivo studies of concentration-dependent antiviral activity to support the dose selection ...
What is the current status of trial NCT05408091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-09-14. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT05408091?
The interventions under investigation include: TRL345, a human monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT05408091?
This trial is sponsored by Trellis Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05408091's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI